Integrated Biomimetic Platform for Enhancing the Efficient Capture and Visual Identification of Circulating Tumor Cells

The nondestructive capture and direct identification of circulating tumor cells (CTCs) have emerged as the critical technologies in modern oncology for oncology research, clinical diagnosis, and personalized therapy optimization. However, technical challenges still exist due to the extreme rarity and significant phenotypic heterogeneity. Herein, we present an innovative biomimetic detection platform engineered by integrating platelet membrane-camouflaged magnetic beads (PM-MBs) with rolling circle amplification (RCA)-synthesized aptamer-based polyvalent antibody mimics (PAMs), which is abbreviated as PM-PAM platform. This dual-functional PM-PAM platform demonstrates exceptional CTC capture efficiency (>90%) while enabling instrument-free visual detection of trophoblast cell surface antigen 2 (Trop-2) expression through metal-organic framework (MOF) nanozyme-based colorimetric signals. Triple-negative breast cancer (TNBC) patients undergoing sacituzumab govitecan (SG) therapy suggests CTCs can be successfully detected. Meanwhile, concurrent visual assessment of Trop-2 expression levels on captured cells can be realized. With the unique advantages of cell viability preservation, 100% diagnostic specificity, modular design adaptability, and cost-effectiveness, the PM-PAM platform establishes a new paradigm for liquid biopsy applications. This technology also shows the particular promise for monitoring antibody-drug conjugate (ADC) treatment efficacy through dynamic Trop-2 expression analysis in breast cancer management.